Nexium Control (Esomeprazole)

Esomeprazole, the active ingredient in Nexium Control, is a proton pump inhibitor presented as an oral tablet for oral use. It suppresses gastric acid secretion and is indicated for gastro‑oesophageal reflux disease, erosive oesophagitis, heartburn relief, prevention of NSAID‑induced ulcers, and as part of Helicobacter pylori eradication regimens, primarily marketed in the European Union.

GNH USA supplies Nexium Control as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including major academic medical centres and community health providers.

Esomeprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Erosive oesophagitis: facilitates mucosal healing and reduces further acid damage. - NSA‑induced gastric ulcer prevention: lowers risk of ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs. - Helicobacter pylori eradication (in combination therapy): enhances eradication rates when used with antibiotics and a clarithromycin‑based regimen.

Esomeprazole may be associated with a range of adverse reactions, which are generally categorized by frequency. Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools, often transient. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis requiring medical attention. - Acute interstitial nephritis: inflammation of kidney interstitium. - Hypomagnesemia: low serum magnesium levels with prolonged use. - Stevens‑Johnson syndrome: rare severe skin reaction.

When prescribing or dispensing esomeprazole, several safety considerations should be observed. - Assess renal function: dose adjustment may be required in severe impairment. - Review concomitant medications: avoid use with drugs that require acidic gastric pH for absorption. - Monitor long‑term therapy: consider periodic evaluation of magnesium levels and bone health. - Use with caution in elderly: higher risk of fractures and renal complications. - Pregnancy and lactation: evaluate risk‑benefit; limited data available. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture.

Esomeprazole can affect the plasma concentrations of several co‑administered medicines. Major Interactions (Avoid): - Ketoconazole and itraconazole: reduced absorption leading to therapeutic failure. - Atazanavir and nelfinavir: markedly decreased antiviral efficacy. - Clopidogrel: diminished antiplatelet effect increasing cardiovascular risk. Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation. - Digoxin: possible increase in serum levels, observe for toxicity. - Methotrexate (high dose): reduced renal clearance, watch for toxicity.